Pax World Management Lowers stake in Becton Dickinson and Co (BDX)

Becton Dickinson and Co (BDX) : Pax World Management reduced its stake in Becton Dickinson and Co by 37.4% during the most recent quarter end. The investment management company now holds a total of 167,187 shares of Becton Dickinson and Co which is valued at $27.8 Million after selling 99,896 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on May 11, 2016.Becton Dickinson and Co makes up approximately 1.50% of Pax World Management’s portfolio.

Other Hedge Funds, Including , Bank Of The Ozarks reduced its stake in BDX by selling 27 shares or 1.88% in the most recent quarter. The Hedge Fund company now holds 1,413 shares of BDX which is valued at $232,919. Becton Dickinson and Co makes up approx 0.09% of Bank Of The Ozarks’s portfolio.Montag A Associates Inc reduced its stake in BDX by selling 500 shares or 7.85% in the most recent quarter. The Hedge Fund company now holds 5,871 shares of BDX which is valued at $967,776. Becton Dickinson and Co makes up approx 0.14% of Montag A Associates Inc’s portfolio.Rothschild Investment Corp Il boosted its stake in BDX in the latest quarter, The investment management firm added 7 additional shares and now holds a total of 2,753 shares of Becton Dickinson and Co which is valued at $443,949. Becton Dickinson and Co makes up approx 0.06% of Rothschild Investment Corp Il’s portfolio.

Becton Dickinson and Co opened for trading at $166.29 and hit $168.86 on the upside on Monday, eventually ending the session at $168.57, with a gain of 1.37% or 2.28 points. The heightened volatility saw the trading volume jump to 10,00,764 shares. Company has a market cap of $35,771 M.

On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.

Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Leave a Reply

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.